Practical implication
Regulatory compliance workflows involving the Dengue Tetravalent Vaccine outside the EU need to incorporate the EMA's positive opinion concerning its use in individuals aged 4 to 60.
The European Medicines Agency (EMA) has posited an opinion for the Dengue Tetravalent Vaccine (Live, Attenuated) Takeda, indicating its use for the prevention of dengue disease in individuals aged 4 to 60 outside the EU. This positive opinion, stemming from an assessment conducted under Regulation (EC) No 726/2004, may influence compliance evaluations and safety assessments regarding the vaccine's deployment.
What changed: The EMA has issued an opinion that endorses the use of the Dengue Tetravalent Vaccine outside the EU for individuals aged 4 to 60, marking a significant regulatory position.
Why it matters: This opinion affects regulatory protocols concerning the vaccine, particularly in terms of compliance and safety assessments for its administration in non-EU countries.
Practical implication: Regulatory compliance workflows involving the Dengue Tetravalent Vaccine outside the EU need to incorporate the EMA's positive opinion concerning its use in individuals aged 4 to 60.
View original source
- Source: EMA - What's new RSS
- Published at source: 2026-09-04T00:00:00.000Z
- Discovered by monitor: 2026-09-04T21:35:10.373Z
Published from the regulator source ingestion pipeline after PV impact triage.
